Anemia Treatment Market to Reach USD 14.9 Billion by 2028, Growing at a 6.9% CAGR

Anemia Treatment Market
Anemia Treatment Market

The global anemia treatment market is on a steady growth path, with sales expected to exceed USD 10.0 billion in 2022. Bolstered by a compound annual growth rate (CAGR) of 6.9%, the market is forecasted to achieve a valuation of USD 14.9 billion by 2028.

Anemia, a condition characterized by a lack of healthy red blood cells or hemoglobin, continues to be a significant global health concern. The rising prevalence of anemia, driven by factors such as malnutrition, chronic diseases, and aging populations, is propelling the demand for effective treatment solutions.

Key Market Drivers:

  • Increased awareness and screening for anemia in both developed and developing regions.
  • Advancements in treatment options, including targeted therapies and new-generation biologics.
  • Expanding access to healthcare services, particularly in emerging economies.

Competition Landscape

Leading players operating in the global anemia treatment market are focusing on adopting various marketing strategies to expand their geographical presence and product portfolios. Some of the other key players are striving to join hands with international and local retailers to distribute their in-house acute anemia treatment medications. Meanwhile, a few renowned companies are aiming to develop innovative drugs and gain approval from regulatory bodies for marketing. For instance:

  • In February 2022, the USA Food and Drug Administration (FDA) approved Pyrukynd (mitapivat) tablets for the treatment of hemolytic anemia in adult patients living with Pyruvate Kinase (PK) deficiency. The drug’s effectiveness was evaluated by conducting two studies. In the single-arm study, its effectiveness was examined based on the reduction in transfusion burden, whereas in the randomized study, it was based on the hemoglobin response.
  • In February 2022, the European Commission approved Global Blood Therapeutics, Inc.’s Oxbryta (voxelotor) to treat hemolytic anemia in patients suffering from sickle cell disease between the age group of 12 years and above. It is the first medicine that was approved in Europe for destroying red blood cells and directly inhibiting the molecular basis of sickling.

Key Companies Profiled

Amgen Inc.; Hoffmann-La Roche Ltd.; Novartis AG; Pfizer Inc.; Janssen Pharmaceuticals, Inc.; Teva Pharmaceutical Industries Ltd.; AMAG Pharmaceuticals; Rockwell Medical; Akebia Therapeutics; Vifor Pharma Management Ltd.

A Comprehensive Full Report

Anemia Treatment Market by Category

By Treatment:

  • Medications
  • Dietary Supplements

By Disease:

  • Normocytic anemia
  • Microcytic anemia
  • Macrocytic anemia

By Distribution Channel:

  • Institutional Pharmacies
  • Retail Pharmacies
  • Mail Order Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogs | YouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these